285 related articles for article (PubMed ID: 14551143)
1. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents.
Cragg MS; Glennie MJ
Blood; 2004 Apr; 103(7):2738-43. PubMed ID: 14551143
[TBL] [Abstract][Full Text] [Related]
2. Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines.
Cardarelli PM; Quinn M; Buckman D; Fang Y; Colcher D; King DJ; Bebbington C; Yarranton G
Cancer Immunol Immunother; 2002 Mar; 51(1):15-24. PubMed ID: 11845256
[TBL] [Abstract][Full Text] [Related]
3. A complement-dependent cytotoxicity-enhancing anti-CD20 antibody mediating potent antitumor activity in the humanized NOD/Shi-scid, IL-2Rγ(null) mouse lymphoma model.
Sato F; Ito A; Ishida T; Mori F; Takino H; Inagaki A; Ri M; Kusumoto S; Komatsu H; Iida S; Okada N; Inagaki H; Ueda R
Cancer Immunol Immunother; 2010 Dec; 59(12):1791-800. PubMed ID: 20714721
[TBL] [Abstract][Full Text] [Related]
4. Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation.
Beers SA; Chan CH; James S; French RR; Attfield KE; Brennan CM; Ahuja A; Shlomchik MJ; Cragg MS; Glennie MJ
Blood; 2008 Nov; 112(10):4170-7. PubMed ID: 18583569
[TBL] [Abstract][Full Text] [Related]
5. Complement activation determines the therapeutic activity of rituximab in vivo.
Di Gaetano N; Cittera E; Nota R; Vecchi A; Grieco V; Scanziani E; Botto M; Introna M; Golay J
J Immunol; 2003 Aug; 171(3):1581-7. PubMed ID: 12874252
[TBL] [Abstract][Full Text] [Related]
6. Complement-Dependent Activity of CD20-Specific IgG Correlates With Bivalent Antigen Binding and C1q Binding Strength.
Bondza S; Marosan A; Kara S; Lösing J; Peipp M; Nimmerjahn F; Buijs J; Lux A
Front Immunol; 2020; 11():609941. PubMed ID: 33505398
[TBL] [Abstract][Full Text] [Related]
7. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts.
Cragg MS; Morgan SM; Chan HT; Morgan BP; Filatov AV; Johnson PW; French RR; Glennie MJ
Blood; 2003 Feb; 101(3):1045-52. PubMed ID: 12393541
[TBL] [Abstract][Full Text] [Related]
8. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms.
Harjunpää A; Junnikkala S; Meri S
Scand J Immunol; 2000 Jun; 51(6):634-41. PubMed ID: 10849376
[TBL] [Abstract][Full Text] [Related]
9. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.
Liu C; DeNardo G; Tobin E; DeNardo S
Cancer Biother Radiopharm; 2004 Oct; 19(5):545-61. PubMed ID: 15650447
[TBL] [Abstract][Full Text] [Related]
10. Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients.
Beurskens FJ; Lindorfer MA; Farooqui M; Beum PV; Engelberts P; Mackus WJ; Parren PW; Wiestner A; Taylor RP
J Immunol; 2012 Apr; 188(7):3532-41. PubMed ID: 22368276
[TBL] [Abstract][Full Text] [Related]
11. Unique toxicities and resistance mechanisms associated with monoclonal antibody therapy.
Friedberg JW
Hematology Am Soc Hematol Educ Program; 2005; ():329-34. PubMed ID: 16304399
[TBL] [Abstract][Full Text] [Related]
12. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX.
Pawluczkowycz AW; Beurskens FJ; Beum PV; Lindorfer MA; van de Winkel JG; Parren PW; Taylor RP
J Immunol; 2009 Jul; 183(1):749-58. PubMed ID: 19535640
[TBL] [Abstract][Full Text] [Related]
13. The Construction and Characterization of 1F5 Chimeric Anti-CD20 Monoclonal Antibodies: An Efficient Splicing by Overlap Extension-polymerase Chain Reaction Technique.
Khademi F; Mohammadi P; Mostafaei A
Iran J Allergy Asthma Immunol; 2021 Apr; 20(2):205-220. PubMed ID: 33904679
[TBL] [Abstract][Full Text] [Related]
14. Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells.
Engelberts PJ; Voorhorst M; Schuurman J; van Meerten T; Bakker JM; Vink T; Mackus WJ; Breij EC; Derer S; Valerius T; van de Winkel JG; Parren PW; Beurskens FJ
J Immunol; 2016 Dec; 197(12):4829-4837. PubMed ID: 27807190
[TBL] [Abstract][Full Text] [Related]
15. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells.
Shan D; Ledbetter JA; Press OW
Cancer Immunol Immunother; 2000 Mar; 48(12):673-83. PubMed ID: 10752475
[TBL] [Abstract][Full Text] [Related]
16. Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies.
Bornstein GG; Quéva C; Tabrizi M; van Abbema A; Chavez C; Wang P; Foord O; Ahluwalia K; Laing N; Raja S; Wen S; Green LL; Yang X; Webster C; Stewart R; Blakey D
Invest New Drugs; 2010 Oct; 28(5):561-74. PubMed ID: 19626278
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.
Betting DJ; Yamada RE; Kafi K; Said J; van Rooijen N; Timmerman JM
J Immunother; 2009; 32(6):622-31. PubMed ID: 19483647
[TBL] [Abstract][Full Text] [Related]
18. Engineered anti-CD20 antibodies with enhanced complement-activating capacity mediate potent anti-lymphoma activity.
Natsume A; Shimizu-Yokoyama Y; Satoh M; Shitara K; Niwa R
Cancer Sci; 2009 Dec; 100(12):2411-8. PubMed ID: 19758394
[TBL] [Abstract][Full Text] [Related]
19. Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab.
Stein R; Qu Z; Chen S; Solis D; Hansen HJ; Goldenberg DM
Blood; 2006 Oct; 108(8):2736-44. PubMed ID: 16778139
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a novel humanized anti-CD20 antibody with potent anti-tumor activity against non-Hodgkin's lymphoma.
Zhang H; Song L; Ye H; Hu L; Liang W; Liu D
Cell Physiol Biochem; 2013; 32(3):645-54. PubMed ID: 24022075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
